Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
NADMED Ltd. logo — The standard of NAD measuring.

NADMED Ltd.

The standard of NAD measuring.

Founded 2022 Finland Finland 20 employees Seed Total: $3.50M Biotechnology

General Information

Company Name NADMED Ltd.
Founded Year 2022
Location Finland Finland
Employees 20
Industries Biotechnology
Funding Stage Seed
Business Model B2B, D2C, B2D
Revenue Model Product Sales, Service Fee, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with NADMED Ltd.. To contact NADMED Ltd., visit nadmed.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NADMED Ltd. compare?

A PDF of NADMED Ltd. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NADMED Ltd. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NADMED Ltd.

NADMED Ltd., founded in 2022, is a biotechnology startup based in Finland. The company has rapidly made a name for itself in the industry with its innovative approach to measuring NADs from whole blood and other sample matrices. With the slogan, "The standard of NAD measuring," NADMED Oy has introduced a high-throughput method that stands out for its accuracy and potential to revolutionize diagnostics.

The company recently secured a $3.50M grant investment on 01 August 2024 from notable investors including Voima Ventures, University of Helsinki, and Nordic Science Investments. This financial backing from respected institutions underscores confidence in NADMED's technology and growth potential within the biotechnology landscape.

Positioned at the intersection of innovation and precision, NADMED Ltd. exemplifies a compelling opportunity for venture capitalists looking to invest in groundbreaking solutions in the biotech sector.

Business keywords: NAD measurement, High-throughput testing, In Vitro Diagnostics, Mitochondrial diseases, Metabolite extraction, NAD metabolism, NAD test kits, Glutathione measurement, Rare diseases, Longevity research, Blood testing equipment, NAD+ research, Laboratory diagnostics

Services & Products

NAD+ and NADH Blood Kits
Laboratory Analysis Services
NAD Metabolite Quantification
Scientific Collaboration and Research Support

Target Customers

Clinical Laboratories Research Institutions Healthcare Providers Biotechnology Companies Pharmaceutical Companies

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $3.50M 3
Voima Ventures
Voima Ventures, University of Helsinki +1
01 Aug 2024
Seed Undisclosed 2
Voima Ventures
Voima Ventures, University of Helsinki
01 Jun 2022
Spinout Undisclosed 1
University of Helsinki
01 Jan 2022

Latest News

View All
Brevo becomes unicorn after a €500M round, Bending Spoons acquires EventBrite, and Europe's biggest... — Tech
Brevo becomes unicorn after a €500M round, Bending Spoons acquires EventBrite, and Europe's biggest H1 edtech deals
Tech Dec 05, 2025
Biotech scaleup NADMED launches $30K global award to advance innovation in cellular health — Tech
Biotech scaleup NADMED launches $30K global award to advance innovation in cellular health
Tech Dec 02, 2025
Finnish biotech NADMED raises €3.5 million Series A for vitamin B3 deficiencies testing — Eu-startups
Finnish biotech NADMED raises €3.5 million Series A for vitamin B3 deficiencies testing
Eu-startups Aug 22, 2024
Biotech NADMED raises €3.5M series A for 'NAD' vitals testing — Tech
Biotech NADMED raises €3.5M series A for 'NAD' vitals testing
Tech Aug 22, 2024
Finnis biotech NADMED raises €3.5 million Series A for vitamin B3 deficiencies testing — Eu-startups
Finnis biotech NADMED raises €3.5 million Series A for vitamin B3 deficiencies testing
Eu-startups Aug 22, 2024

NADMED Ltd. Alternatives & Competitors

View All Alternatives
NADMED Ltd. vs
Sentromer DNA Technologies Inc.
Sentromer DNA Technologies Inc. Turkey

We make it from scratch!

3 employees
Biotechnology, Health Care
NADMED Ltd. vs
Biopanda Reagents
Biopanda Reagents United Kingdom

Responsible Diagnostic Solutions

4 employees
Biotechnology, Industrial
NADMED Ltd. vs
Cellular Technology Limited — CTL
Cellular Technology Limited — CTL United States

Enabling and empowering the immune monitoring community around the world with innovative products an...

121 employees
Biotechnology, Information Technology
View all alternatives

FAQ About NADMED Ltd.

The standard of NAD measuring.
NADMED Ltd. was founded in 2022.
NADMED Ltd. is headquartered in Finland.
NADMED Ltd. operates in Biotechnology. Its work centres on NAD measurement, High-throughput testing, In Vitro Diagnostics and Mitochondrial diseases. Its customers include Clinical Laboratories, Research Institutions and Healthcare Providers.
NADMED Ltd. has a B2B, D2C and B2D business model. Its revenue comes from Product Sales, Service Fee and Usage Based.
NADMED Ltd. has approximately 20 employees.
NADMED Ltd. has completed 3 funding rounds, raising a total of $3.50M. The latest funding stage is Seed.
NADMED Ltd. offers: NAD+ and NADH Blood Kits, Laboratory Analysis Services, NAD Metabolite Quantification, Scientific Collaboration and Research Support.
Top alternatives and competitors to NADMED Ltd. include Sentromer DNA Technologies Inc., Biopanda Reagents, Cellular Technology Limited — CTL, PrognomiQ Inc, MGI. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NADMED Ltd. and Sentromer DNA Technologies Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NADMED Ltd., https://bouncewatch.com/company/nadmed, updated 13 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout